These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 8247036

  • 1. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer.
    Arriagada R, Le Chevalier T, Pignon JP, Rivière A, Monnet I, Chomy P, Tuchais C, Tarayre M, Ruffié P.
    N Engl J Med; 1993 Dec 16; 329(25):1848-52. PubMed ID: 8247036
    [Abstract] [Full Text] [Related]

  • 2. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.
    Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH.
    N Engl J Med; 1999 Jan 28; 340(4):265-71. PubMed ID: 9920950
    [Abstract] [Full Text] [Related]

  • 3. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis.
    Spiro SG, James LE, Rudd RM, Trask CW, Tobias JS, Snee M, Gilligan D, Murray PA, Ruiz de Elvira MC, O'Donnell KM, Gower NH, Harper PG, Hackshaw AK, London Lung Cancer Group.
    J Clin Oncol; 2006 Aug 20; 24(24):3823-30. PubMed ID: 16921033
    [Abstract] [Full Text] [Related]

  • 4. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
    Chen GY, Jiang GL, Wang LJ, Qian H, Fu XL, Yang H, Wu KL, Zhao S.
    Int J Radiat Oncol Biol Phys; 2005 Jan 01; 61(1):70-5. PubMed ID: 15629596
    [Abstract] [Full Text] [Related]

  • 5. Limited small cell lung cancer: possible prognostic impact of initial chemotherapy doses.
    Arriagada R, de The H, Le Chevalier T, Thomas F, Ruffie P, de Cremoux H, Martin M, Duroux P, Dewar J, Sancho-Garnier H.
    Bull Cancer; 1989 Jan 01; 76(6):604-15. PubMed ID: 2550102
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Surgical treatment for limited small-cell lung cancer. The University of Toronto Lung Oncology Group experience.
    Shepherd FA, Ginsberg RJ, Feld R, Evans WK, Johansen E.
    J Thorac Cardiovasc Surg; 1991 Mar 01; 101(3):385-93. PubMed ID: 1847981
    [Abstract] [Full Text] [Related]

  • 8. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S, Norwegian Lung Cancer Study Group.
    Lung Cancer; 2005 May 01; 48(2):251-61. PubMed ID: 15829326
    [Abstract] [Full Text] [Related]

  • 9. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.
    Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, Johnson DH.
    N Engl J Med; 2000 Oct 26; 343(17):1217-22. PubMed ID: 11071672
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer.
    Schild SE, Bonner JA, Shanahan TG, Brooks BJ, Marks RS, Geyer SM, Hillman SL, Farr GH, Tazelaar HD, Krook JE, Geoffroy FJ, Salim M, Arusell RM, Mailliard JA, Schaefer PL, Jett JR.
    Int J Radiat Oncol Biol Phys; 2004 Jul 15; 59(4):943-51. PubMed ID: 15234027
    [Abstract] [Full Text] [Related]

  • 13. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
    Ariyoshi Y, Fukuoka M, Furuse K, Saijo N, Ikegami H, Nishiwaki Y, Tamura T, Shimoyama M, Suemasu K.
    Jpn J Clin Oncol; 1994 Oct 15; 24(5):275-81. PubMed ID: 7967106
    [Abstract] [Full Text] [Related]

  • 14. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
    Cetingöz R, Cetinayak HO, Sen RC, Demiral AN, Akkoçlu A, Osma E, Kargi A, Oztop I, Onen A, Kinay M, Dokuz Eylül Lung Cancer Study Group.
    J BUON; 2006 Oct 15; 11(1):31-7. PubMed ID: 17318949
    [Abstract] [Full Text] [Related]

  • 15. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.
    Shepherd FA, Evans WK, MacCormick R, Feld R, Yau JC.
    Cancer Treat Rep; 1987 Oct 15; 71(10):941-4. PubMed ID: 2820571
    [Abstract] [Full Text] [Related]

  • 16. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer.
    Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei EF, Green MR.
    N Engl J Med; 1990 Oct 04; 323(14):940-5. PubMed ID: 2169587
    [Abstract] [Full Text] [Related]

  • 17. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K, Wolf M, Drings P, Hans K, Schroeder M, Holle R, Flechtner H, Goerg R, Becker H.
    Semin Oncol; 1989 Feb 04; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [Abstract] [Full Text] [Related]

  • 18. [Pilot study of dose intensive weekly chemotherapy followed by cisplatin plus etoposide with concurrent thoracic irradiation for limited-disease small-cell lung cancer. West Japan Thoracic Oncology Group].
    Isobe T, Fukuoka M, Negoro S, Sugiura T, Kawahara M, Kudoh S, Araki J, Nakagawa K, Yokozaki M, Yamakido M, Ariyoshi Y.
    Gan To Kagaku Ryoho; 2000 Jul 04; 27(8):1091-6. PubMed ID: 10945001
    [Abstract] [Full Text] [Related]

  • 19. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up.
    Ueoka H, Kiura K, Tabata M, Kamei H, Gemba K, Sakae K, Hiraki Y, Hiraki S, Segawa Y, Harada M.
    Cancer; 1998 Jul 15; 83(2):283-90. PubMed ID: 9669811
    [Abstract] [Full Text] [Related]

  • 20. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
    Ardizzoni A, Fusco V, Pennucci C, Baldini E, Orsatti M, Vitale V, Bonavia M, Baracco F, Mereu C, Rosso R.
    Anticancer Res; 1991 Jul 15; 11(2):681-4. PubMed ID: 1648333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.